MedTrace Logo

Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC

NCT02577627 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2017-04-04

No results posted yet for this study

Summary

This is a retrospective observational, open label study to evaluate and prospectively validate in a blind manner the accuracy of predicting treatment outcomes by PrediCare in individual patients with Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Castration-Resistant Prostate Cancer, Breast Cancer \& Colon Cancer under the treatment with the mono- and combination drug protocols for the 1st and 2nd line treatment, approved to the market as a Standard of Care

Conditions

Interventions

DEVICE

PrediCare

Sponsors & Collaborators

  • Optimata Ltd.

    lead INDUSTRY

Principal Investigators

  • Marina Kleiman, PhD · Optimata Ltd.

  • Irina Lazarov, MD · Soroka University Medical Center

  • Maya Gottfried, MD · Meir Medical Center, Kfar Saba, Israel

  • Noa Efrat (Ben-Baruch), MD · Kaplan Medical Center, Rehovot, Israel

  • Mor Moskovitz, MD · Rambam Medical Center, Haifa, Israel

  • Avishay Sela, MD · Assaf Harofeh Medical Center, Zrifin, Israel

  • Ronen Brenner, MD · Wolfson Medical Center

  • Hovav Nehushtan, MD · Hadassah Medical Center, Jerusalem

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2018-01-31
Completion
2019-09-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02577627 on ClinicalTrials.gov